New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
05:59 EDTBIIB, GILDStocks with implied volatility movement; BIIB GILD
Stocks with implied volatility movement; Biogen (BIIB) 38, Gilead (GILD) 34 according to iVolatility.
News For BIIB;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 22, 2014
10:56 EDTGILDGilead sell-off on HCV deal 'way overdone,' says UBS
UBS says today's sell-off in shares of Gilead (GILD) is "way overdone." It views Express Scripts' (ESRX) deal with AbbVie (ABBV) as an incremental negative given the reach of the pharmacy benefits manager's coverage, but thinks the $15B taken off of Gilead's market cap is excessive. The firm estimates Express Scripts' formulary change will impact 30K-40K hepatitis C cases in 2015 out of the 177K treated. UBS thinks Gilead can still retain the majority of non-Express Scripts HCV business. It has a Buy rating on the stock with a $125 price target. Shares of the drug maker are down $13.64 to $94.81 in morning trading.
10:40 EDTGILDGilead shares defended at UBS
Subscribe for More Information
10:00 EDTGILDGilead volatility increases after Express Scripts picks AbbVie for hepatitis C
Subscribe for More Information
09:38 EDTGILDActive equity options trading
Subscribe for More Information
09:35 EDTGILDGilead drops sharply, levels to watch
The stock is down over 13.3% to $94.20 at time of writing. At that price support is at the session low at $93.36 and then at $92.79. Resistance is at $96.88.
09:24 EDTGILDOn The Fly: Pre-market Movers
HIGHER: Caesars Entertainment (CZR), up 23.8% following agreement to merge with Caesars Acquisition (CACQ)... Synthetic Biologics (SYN), up 8.6% following positive topline results from SYN-004 Phase 1a trial... Advaxis (ADXS), up 6.1% after Adage Capital Partners reports 18.84% passive stake in Advaxis... TASER (TASR), up 4.25% following multiple orders of Smart Weapons and Conducted Electrical Weapons... BioCryst Pharmaceuticals (BCRX), up 3.4% after RAPIVAB receives FDA approval... Herbalife (HLF), up 1.4% following a New York Post report that the FDA asked the company to stop airing a video claiming FDA approval. LOWER: Ocwen Financial (OCN), down 10.5% following settlement agreement with New York Department of Financial Services. NOTABLE: Enanta Pharmaceuticals (ENTA), up 11.8% following FDA approval of AbbVie's Viekira Pak... AbbVie is (ABBV) is up 2.4% following FDA approval of Viekira Pak and that Express Scripts (ESRX) will expand access to Viekira Pak... Express Scripts is trading marginally higher... Gilead Sciences (GILD), down 11.3% after Express Scripts picks AbbVie for hepatitis C.
09:19 EDTGILDHigher than expected Abbvie HCV drug pricing positive for Gilead, says UBS
Subscribe for More Information
08:54 EDTGILDExpress Scripts says hoping more companies take AbbVie view on opening access
Express Scripts (ESRX) CEO George Paz says AbbVie's (ABBV) Hep C drug compliance was "really high" in trials and that the company was focused on opening up access to its drug with the deal it struck with Express Scripts. Paz believes drug prices are "unsustainable" at recent levels and he believes deals like the one his company struck with AbbVie can be extended to other therapeutic areas. Paz was speaking on CNBC.
08:01 EDTGILDAASLD publishes new recommendations for treating Hepatitis C
Subscribe for More Information
06:29 EDTGILDGilead drops 4% after Express Scripts picks AbbVie for hepatitis C
Shares of Gilead (GILD) are moving lower in pre-market trading after Express Scripts (ESRX) spokesman Brian Henry told CNBC's Meg Tirrell and other news outlets that the pharmacy benefits manger will exclusively offer AbbVie's (ABBV) recently approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1. Express Scripts will no longer offer competing drugs from Gilead and Johnson & Johnson (JNJ). Shares of AbbVie are rising 6% to $71.50 in pre-market trading while Gilead is down 4% to $104.15. AbbVie discovered part of the Viekira Pak regimen via its ongoing collaboration with Enanta Pharmaceuticals (ENTA). Shares of Enanta are up 7% to $49.96 in pre-open trading.
05:44 EDTGILDExpress Scripts to offer AbbVie hepatitis C drug exclusively, CNBC reports
Express Scripts (ESRX) will offer AbbVie's (ABBV) just approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1, while excluding competing drugs from Gilead (GILD) and Johnson & Johnson (JNJ), CNBC's Meg Tirrell reports, citing comments from the pharmacy benefits manager's spokesman Brian Henry. Reference Link
December 19, 2014
16:01 EDTGILDOptions Update; December 19, 2014
iPath S&P 500 VIX Short-Term Futures down 27c to 29.90. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX according to Track Data.
09:48 EDTBIIBBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
09:37 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL TSLA BBRY AMZN CELG GILD JCP AMAT FB
08:53 EDTBIIBBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
08:51 EDTBIIBBiogen drops 2% after Roche discontinues Alzheimer drug trial
Shares of Biogen (BIIB) are moving lower after Roche (RHHBY) announced the discontinuation of its Alzheimer's drug gantenerumab, which was in Phase III testing. Analysts at Wells Fargo said Roche's trial failure adds risk to Biogen's potential treatment of Alzheimer's. Shares of Biogen are down $8.20 to $345.50 in pre-market trading.
05:31 EDTGILDGilead, ONO announce exclusive license agreement to develop ONO-4059
ONO PHARMACEUTICAL and Gilead Sciences announced that the companies have entered into an exclusive license agreement for the development and commercialization of ONO-4059, ONOís oral Brutonís tyrosine kinase, or BTK, inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead will pay ONO an upfront payment plus additional payments based upon achievement of certain development, regulatory and commercial milestones. The companies will collaborate jointly on global development of ONO-4059. Gilead will have exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China and the Association of Southeast Asian Nations, or ASEAN, countries, where ONO retains development and commercialization rights. ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. ONO has presented preliminary Phase 1 data showing clinical activity in chronic lymphocytic leukemia and non-Hodgkin lymphoma at several scientific conferences. ONO and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gileadís portfolio.
December 18, 2014
09:35 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL FB TSLA PBR RAD AMAT NFLX GILD KMI TWTR
December 17, 2014
09:41 EDTGILDActive equity options trading
Subscribe for More Information
December 16, 2014
16:00 EDTGILDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use